Search

Nowa tabletka odchudzająca Foundayo, opracowana przez Eli Lilly i zawierająca substancję czynną orforglipron, została dopuszczona do użytku po rygorystycznej ocenie jej bezpieczeństwa i skuteczności, co może zwiększyć dostępność terapii odchudzającej w Europie. #Foundayo #orforglipron #odchudzanie

El artículo destaca cómo España se ha convertido en un centro estratégico para la industria farmacéutica, siendo hogar de la producción de medicamentos icónicos como la Aspirina y el Ventolín, así como de innovaciones recientes como la pastilla orforglipron de Lilly para la obesidad, que ejemplifican la combinación de tradición y avanzada investigación en el país. #IndustriaFarmacéutica #MedicamentosInnovadores #España

Studije predstavljene na konferenciji OMA u SAD-u pokazale su da oralni semaglutid značajno brže dovodi do gubitka težine u usporedbi s orforglipronom, pri čemu devet od deset ispitanika preferira semaglutid zbog učinkovitosti i načina primjene. #semaglutid #mršavljenje #oralni oblici terapije

V članku se poroča o novi tableti orforglipron, ki deluje podobno kot trenutne injekcije za hujšanje, saj zmanjšuje apetit in pomaga ohranjati izgubljeno težo, kar bi lahko predstavljalo privlačno alternativo za bolnike, ki se spopadajo z obnavljanjem telesne teže po prenehanju zdravljenja. #debelenje #zdravljenje #hujšanje

A new daily pill, orforglipron, may help individuals who stop using injectable weight-loss medications maintain their weight loss, as research indicates that patients using the pill were able to keep over 70% of the weight they lost, while those on a placebo maintained only 38-50%, with the study highlighting orforglipron's potential benefits in managing obesity as a chronic disease. #WeightLoss #ObesityTreatment #HealthInnovation #US #GB

A new daily pill called orforglipron may help individuals who stop using injectable weight loss medications maintain their weight loss, as a study shows that those taking the pill retained over 70% of their lost weight after a year, compared to 38-50% for the placebo group, with further research needed to determine the long-term effects of the treatment. #WeightLoss #ObesityTreatment #HealthResearch #US #GB

A new daily pill, orforglipron, has shown promise in helping individuals maintain weight loss after stopping injectable weight loss medications, with study participants who took the pill retaining over 70% of their weight loss, while those on a placebo maintained only 38-50%, suggesting a potential shift in obesity treatment methods. #WeightLoss #ObesityTreatment #HealthResearch #US #GB

Novo istraživanje pokazuje da bi orforglipron, dnevna tableta, mogla pomoći ljudima da zadrže izgubljene kilograme nakon prestanka korištenja injekcija za mršavljenje, čime bi se potencijalno smanjila potreba za drugim lijekovima povezanima s pretilošću i preveniralo više od 200 bolesti. #pretilost #mršavljenje #orforglipron

A new pill called orforglipron may help prevent weight regain in individuals who have stopped using weight loss injections, with research indicating that those taking it daily for a year maintained over 70% of their initial weight loss, and its potential for broader availability following approval in the U.S. and possibly the U.K. soon. #WeightLoss #ObesityTreatment #HealthResearch #US #GB

A new daily pill, orforglipron, may help individuals maintain weight loss after discontinuing injectable weight loss medications, according to a study published in Nature Medicine, which found that participants taking the pill preserved over 70% of their weight loss compared to 38-50% in the placebo group, suggesting that oral medication could offer a more appealing alternative to injections for long-term obesity management. #WeightLoss #ObesityTreatment #HealthResearch #US #UK

A new pill named orforglipron may help individuals who have stopped using weight-loss injections maintain their weight loss, as a study showed that participants taking the pill daily for a year effectively prevented weight regain, while also improving health markers related to obesity, though further research is needed to determine the long-term effects and optimal duration of treatment. #WeightLoss #ObesityTreatment #HealthResearch #US #GB

A new daily pill called orforglipron may help individuals maintain weight loss after stopping injectable weight loss medications, with a study showing that participants taking orforglipron retained over 70% of their previous weight loss compared to a placebo group, although further research is needed to determine the long-term effects of the treatment. #WeightLoss #ObesityTreatment #HealthBenefits #US #GB

A new pill called orforglipron may help prevent weight regain in individuals who stop using weight-loss injections, demonstrating promising results in a study where participants who took the pill daily maintained over 70% of their initial weight loss after discontinuing GLP-1 injections, highlighting the need for further research on its long-term efficacy and treatment duration. #WeightLoss #ObesityResearch #Medication #US #GB

A new daily pill, orforglipron, could aid individuals in maintaining weight loss after discontinuing injectable weight-loss medications, with a study showing participants who took the pill daily during a year retained over 70% of their previous weight loss compared to 38-50% in those on a placebo, while also potentially mitigating long-term obesity-related health risks. #WeightLoss #ObesityTreatment #ChronicDisease #US #GB

A new pill called orforglipron may help prevent weight regain in individuals who stop using weight loss injections, according to research published in Nature Medicine, which found that patients taking the pill daily for a year maintained over 70% of their weight loss after discontinuing GLP-1 injections; however, experts emphasize the need for further studies on the duration of treatment and its long-lasting effects on obesity management. #WeightLoss #ObesityTreatment #PharmaceuticalResearch #US #UK

A new pill called orforglipron may help individuals who stop using weight loss injections maintain their weight loss, with a study showing that those taking the pill for a year significantly prevented weight gain after discontinuing GLP-1 injections, although further research is needed to determine its long-term usage and effects. #ObesityManagement #WeightLoss #HealthResearch #US #GB

A new daily pill called orforglipron may help individuals maintain weight loss after stopping GLP-1 injections, with recent trials showing that it allowed participants to retain over 70% of their weight loss, suggesting a promising alternative to injectable treatments. #WeightLoss #ObesityTreatment #HealthResearch #US #UK

Novo istraživanje u časopisu Nature Medicine pokazuje da bi nova dnevna tableta orforglipron, slična injekcijama za mršavljenje, mogla postati doživotni tretman za mršavljenje i prevenciju dijabetesa, budući da je učinkovita u održavanju zdrave težine i smanjenju rizika od komplikacija povezanih s pretilošću. #mršavljenje #pretilost #orforglipron

A new daily pill called orforglipron may help individuals maintain their weight loss after discontinuing GLP-1 injections, with a study showing those who took the pill retained over 70% of their weight loss, while side effects were generally mild, and further research is needed to determine the long-term necessity of the treatment. #WeightLoss #ObesityTreatment #HealthInnovation #US #UK